Skip to main content

Table 5 Cumulative dosimetry estimates obtained in patients having completed three or four evaluable induction cycles (n = 65)

From: Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT

 

Absorbed dose (Gy)

Relative error vs. 3TP (%)

3TP

2TP

1TPD3

2TP/1TPD1

2TP/1TPD3

2TP/NI

2TP

1TPD3

2TP/1TPD1

2TP/1TPD3

2TP/NI

Kidney

19.3

[11.8–23.6]

(6.5–26.3)

19.9

[11.8–24.3]

(6.6–26.7)

18.2

[10.7–24.4]

(4.5–27.2)

17.7

[11.1–24.5]

(6.1–27.0)

17.4

[10.6–23.5]

(4.6–26.6)

17.2

[9.9–25.3]

(4.5–29.3)

1.9

[0.1–3.8]

(− 1.1–8.2)

3.8

[− 24.2–6.3]

(− 39.3–11.1)

− 0.5

[− 26.1–9.6]

(− 41.1–34.4)

0.4

[−28.1–6.4]

(− 40.4–33.2)

− 7.1

[− 32.4–18.0]

(− 42.8–38.3)

Bone marrowtotal

1.10

[0.65–2.23]

(0.52–9.59)

1.07

[0.57–2.15]

(0.48–9.68)

0.89

[0.56–1.97]

(0.38–6.9)

0.80

[0.48–2.59]

(0.32–7.37)

0.86

[0.57–2.35]

(0.38–8.05)

0.86

[0.50–2.35]

(0.40–9.51)

−5.4

[− 9.5 to − 1.4]

(− 19.0–3.9)

13.3

[− 20.5 to − 4.1]

(− 33.2 to − 0.7)

− 15.7

[− 41.4–23.9]

(− 61.2–68.8)

−14.4

[− 24.7–9.0]

(− 57.7–66.4)

−20.3

[− 45.0–27.5]

(− 72.9–110.3)

Tumormax

129.0

[38.7–268.2]

(15.3–473.2)

131.9

[39.9–271.0]

(15.8–466.2)

107.6

[34.1–205.3]

(16.8–390.6)

118.8

[34.1–216.6]

(15.4–402.9)

118.9

[33.6–210.3]

(13.0–416.1)

155.4

[38.8–341.6]

(14.0–575.2)

1.4

[− 0.2–3.3]

(− 1.5–4.3)

−16.1

[− 45.9–3.2]

(− 60.0–12.0)

−5.6

[− 41.0–10.3]

(− 62.7–39.5)

−2.9

[− 40.2–6.4]

(− 63.4–21.9)

15.9

[− 29.2–80.5]

(− 75.6–400.5)

  1. D1 day 1, D3 day 3, NI no imaging, TP time point(s)
  2. Data is presented as median [interdecile range] (range)
  3. Median cumulative injected activity was 30.5 (11.9–78.6) GBq